Salubris Biotherapeutics Inc. has raised $32 million in financing from its parent company, Shenzhen Salubris Pharmaceuticals Co. Ltd., for the development of its cardiovascular candidate. Funds will be used to continue efforts in an ongoing phase Ib trial and to initiate two additional phase Ib studies in 2022, as well as to expand the company’s pipeline.
Prognomiq Inc. nearly doubled its fundraising to date with a new $46 million financing to further develop its multiomics platform to detect cancer and other complex diseases earlier in their development. The financing led by Bruker Corp. along with new investor Catalio Capital Management brought total funds raised $101 million since the company’s founding in 2020.
The Gates Foundation is joining with other philanthropic funders in launching an initiative to develop small-molecule antiviral drugs to lay in as part of preparations for the next pandemic.
Ceros Capital Markets completed a $15 million series D funding round for Pristine Surgical LLC, its latest major investment in the medical device space. The funds will be used to advance the commercialization of Pristine’s single-use visualization platform for surgical and diagnostic endoscopic procedures.
Reflecting enthusiasm for a radiotherapy that can target multiple tumors simultaneously, Reflexion Medical Inc. closed an $80 million series E fundraising round to support development of its biology-guided radiotherapy (BgRT) technology for metastatic cancer. New investors included Ascension Ventures, Catalio Capital Management LP, Sixty Degree Capital Inc. and Hillenbrand Capital Partners LLC.
RSS
